RCM
AEON icon

Radcliffe Capital Management’s AEON Biopharma AEON Stock Holding History

Radcliffe Capital Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,404
Closed -$8.98M – 691
2022
Q4 		$8.98M Hold
12,404
– – 0.28% 66
2022
Q3 		$8.8M Buy
12,404
+369
+3% +$261K 0.21% 78
2022
Q2 		$8.5M Hold
12,035
– – 0.2% 81
2022
Q1 		$8.48M Hold
12,035
– – 0.19% 63
2021
Q4 		$8.42M Hold
12,035
– – 0.22% 54
2021
Q3 		$8.44M Hold
12,035
– – 0.25% 38
2021
Q2 		$8.35M Buy
+12,035
New +$8.41M 0.26% 24

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Radcliffe Capital Management's AEON Position: Q1 2023 in Review

Radcliffe Capital Management sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 12,404 shares — an estimated $8.98M sold.

Radcliffe Capital Management first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $8.98M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Radcliffe Capital Management reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 12,404 AEON Biopharma shares in Q1 2023, an estimated $8.98M.
  • Radcliffe Capital Management first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
  • Radcliffe Capital Management's AEON Biopharma position peaked at $8.98M in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.